Bio-Techne Corporation (BVMF:T1CH34)

Market Cap	62.53B +24.9%
Revenue (ttm)	6.36B +0.9%
Net Income	890.69M +120.5%
EPS	0.20 +125.8%
Shares Out	n/a
PE Ratio	65.53
Forward PE	35.20
Dividend	0.04 (0.28%)
Ex-Dividend Date	Nov 12, 2026

Volume	n/a
Open	13.23
Previous Close	13.23
Day's Range	13.23 - 13.23
52-Week Range	7.34 - 13.30
Beta	1.30
Analysts	n/a
Price Target	n/a
Est. Earnings	Feb 2, 2027

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1976
• Employees: 3,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: T1CH34

Financial Performance

In fiscal year 2026, Bio-Techne's revenue was $1.22 billion, a decrease of -0.38% compared to the previous year's $1.22 billion. Earnings were $181.84 million, an increase of 147.86%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Nov 9, 2026

Data Sources Report a data error